A true predictive biomarker for MASH-HCC must be a “composite” panel that captures: 1) host IR/MASH status; 2) tumor PI3K/Akt/mTOR pathway “imprinting” features; and 3) TME “synergistic evasion” features 143. This evidence concerns the gene MTOR and neoplasm.